Cassava Sciences Inc (NASDAQ:SAVA) CFO Eric Schoen purchased 10,000 shares of Cassava Sciences stock in a transaction on Tuesday, May 14th. The stock was bought at an average price of $1.06 per share, with a total value of $10,600.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
SAVA traded up $0.01 during midday trading on Wednesday, reaching $1.07. The company had a trading volume of 98,092 shares.
Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.08) EPS for the quarter.
About Cassava Sciences
Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
See Also: Do Tariffs Work?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.